NEWS & PRESS

Data supports accuracy and performance of Nucleix’s Bladder Epicheck in NMIBC surveillance

29/09/2020
An independent analysis of studies of Nucleix Ltd.’s Bladder Epicheck demonstrate high diagnostic accuracy and performance in monitoring for disease recurrence...
READ MORE

Independent Review, Published in International Journal of Molecular Sciences, Supports Accuracy and Performance of Nucleix’s Bladder EpiCheck® Urine Test in Detecting Non-Muscle Invasive Bladder Cancer Recurrence

24/09/2020
SAN DIEGO & REHOVOT, Israel--(BUSINESS WIRE)--Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced...
READ MORE

Nucleix Presents Two Bladder EpiCheck® Studies at EAU20 Virtual Congress, Including Interim Data in Patients with Upper Tract Urothelial Cancer

17/07/2020
SAN DIEGO & REHOVOT, Israel- Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced two...
READ MORE

Bladder Cancer Test Enables Painless Follow Up

08/07/2020
Many bladder cancer patients would prefer to not have a cystoscopy - an invasive and painful test – every few...

Nucleix Announces Publication of Data on Methylation-Based Assay for Detecting High-Risk Non-Muscle Invasive Bladder Cancer in Journal of Clinical Pathology

29/06/2020
Bladder EpiCheck® demonstrated superior performance to cytology alone with high sensitivity, specificity and NPV in a high-risk non-muscle invasive bladder...
READ MORE

STAY UPDATED ON THE LATEST NEWS FROM NUCLEIX!

SOCIAL MEDIA

Subscribe to one of our social media channels

close

Subscription Confirmation Required

Go to your email inbox

Go to your email inbox

Go to the inbox of the email
address you just used to sign up.

Open the confirmation email

Open the confirmation email

Find the email sent by us. It has the subject line
“Nucleix: Please Confirm Subscription” and I
sent from “info@nucleix.com”.

Click the confirmation link

Click the confirmation link

Click on the link inside the
email and you’re good to go.

GOT IT !